DD145536A5 - PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO (4,3-B) -INDOLDERIVATE - Google Patents
PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO (4,3-B) -INDOLDERIVATE Download PDFInfo
- Publication number
- DD145536A5 DD145536A5 DD78215015A DD21501578A DD145536A5 DD 145536 A5 DD145536 A5 DD 145536A5 DD 78215015 A DD78215015 A DD 78215015A DD 21501578 A DD21501578 A DD 21501578A DD 145536 A5 DD145536 A5 DD 145536A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- hexahydro
- substituted
- pyrido
- hydrogen
- aryl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- -1 3-chloro-2-butenyl Benzyl Chemical group 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003204 tranquilizing agent Substances 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- WYZFLCYTROCEOJ-UHFFFAOYSA-N 1h-pyrido[4,3-b]indole Chemical class C1=CC=CC2=C3CN=CC=C3N=C21 WYZFLCYTROCEOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- SHKWSBAVRQZYLE-UHFFFAOYSA-N 5-oxo-5-phenylpentanoic acid Chemical class OC(=O)CCCC(=O)C1=CC=CC=C1 SHKWSBAVRQZYLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
-λ--λ-
Verfahren zur Herstellung von Trans~g"-5ubstituierten-5-Aryl-2, 3»4,Aa, 5,9b- * I.H-pyrido (4, 3~b)-indolderivaten Process for the preparation of trans-substituted 5-aryl- 2,3,4-, Aa, 5,9b-, 1H - pyrido (4,3- b) indole derivatives
Anwendungsgebiet der Erfindung: Field of application of the invention :
Die Erfindung betrifft bestirnte trans-2-substituierte~5-Aryl~2,3»4, 4a,5j9fc-hexahydro-1H-pyrido (4,3-b)-indolderivate, die als Tranquilizer geeignet sind,The invention relates to starred trans-2-substituted -5-aryl-2,3,4,4a, 5j9fc-hexahydro-1H-pyrido (4,3-b) indole derivatives useful as tranquilizers.
Charakteristik der bekannten technischen Lösungen;Characteristic of the known technical solutions;
Ira Anschluß an die Einführung von Reserpin und Chlorpromazin in der psychotherapeutischen Medizin in den frühen 19130-Jahreu wurden große Anstrengungen bei der Suche nach anderen Tranquilizern biivJ. Tranquillanten rat verbesserten, biologischen Profilen unternommen, mehrere hiervon sindΫ-Carbolinderivate } die auf dem Fachgebiet auch als Derivate von Pyrido(A,3-b)-indol bekannt sind«Ira's follow-up to the introduction of reserpine and chlorpromazine in psychotherapeutic medicine in the early 19130-yr have been making great efforts in finding other tranquilizers biivJ. Tranquillanten rat improved biological profiles made more thereof are Ϋ -Carbolinderivate} is the in the art as derivatives of pyrido (A, 3-b) indole are known "
In der US-Patentschrift 3 68? 961 wurde 8-Fluor-2~/^~(4-fluorphenyla~ nilonO)-propyl_/~1j2,3,A-teti>ahydro-y-carbolin als brauchbarer Tranquilizer für VJamiblüter beschriebene In der US-Patentschrift 3 755 sind strukturell verwandte Verbindungen rait Fluor in den 6«- oder 8-Stellungen und einer spezifischen, p-substituierten Phenylalkyleinheit in der 2-Stellung als Verbindungen mit ähnlicher Aktivität beschrie- · ben* In U.S. Patent 3,668? 961, 8-fluoro-2 ~ / ^ ~ (4-fluorphenyla ~ nilonO) -propyl_ / ~ 1j2,3, A-teti> ahydro-y-carboline described as useful for tranquilizers VJamiblüter In US Patent 3 755 are structurally related compounds described fluorine in the 6 "or 8 positions and a specific, p-substituted phenylalkyl moiety in the 2-position as compounds with similar activity *
Die US-Patentschrift 3 983 239 beschreibt Hexahydro»/"carbolineU.S. Patent 3,983,239 describes hexahydro-1,4-carboline
1 ·· 21 ·· 2
der Formel a, worin R ein Methyl- oder Athylrest ist und R' ein Wasserstoffatom, ein Methyl- oder Athylrest bedeutet. Die Stereochemische Anordnung der Viasserstoff atome, welche an die Kohlenstoffatome in den 4a- und 9b-Stellungen gebunden sind, ist in dieser Druckschrift nicht erwähnt«, Jedoch ist anzunehmen, daß sie in einer cis-Anordnung vorliegen, und zwar aufgrund der Methode der Bildung des Hexahydro- ^-carbolinringes aus einer 1,2,3,4-Tetrahydro~};wcarbolin-vorläuferverbindung durch katalytische Hydrierung in Anuesenheit von Platin, einer auf dem Fachgebiet wohlbekannten ethode zur Einführung von Wasserstoffatomen in einer cis-Konfiguration in eine Kohlenstoff-Kohlenstoff-Doppelbindung. Die angegebenen Verbindungen sind neuroleptische Mittel, die als zur Behandlung von Schizophrenie brauchbar bezeichnet werden»of formula a, wherein R is a methyl or ethyl radical and R 'represents a hydrogen atom, a methyl or ethyl radical. The stereochemical arrangement of the hydrogen atoms bound to the carbon atoms in the 4a and 9b positions is not mentioned in this document. However, it can be assumed that they are in a cis arrangement because of the method of formation of hexahydro ^ -carbolinringes from a 1,2,3,4-tetrahydro ~}; w carboline-precursor compound by catalytic hydrogenation in Anuesenheit of platinum, a well-known in the art ethod for the introduction of hydrogen atoms in a cis configuration to a carbon -carbon double bond. The compounds mentioned are neuroleptic agents which are considered useful for the treatment of schizophrenia »
In der US-Patentschrift 3 991 199 sind Hexahydropyrimido-(4,3-b)-indole und deren pharmazeutisch verträgliche Salze beschrieben, brauchbar als Analgetika und Sedativa, einige hiervon sind als Tranquilizer, einige als Muskelrelaxantieη von Interesse, und viele dieser Verbindunggen seifeeη hypotensive Aktivität; die beschriebenen Verbindungen besitzen die Formel b, wobei die an den Kohlenstoffatomen in den 4a- und 9b-Stellungen gebundenen Wasserstoffatome in einer trans-Anordnung zueinander vorliegen und worin", wenn Y = -H 'ist, X = -H, -Cl, -Br,-CH-, -tert«~C^H oder -OCH ist, und wenn Ya = -CF3 ist, Xa = -H beddutet und R die Bedeutung hat: Wasserstoff, 3-Chlor~2-butenyi, 2-Broinallyl, Benzyl j am Ring durch Methyl substituiertes Benzyl, Methoxy oder Chlor; Phenäthyl, 3-Phenylpropyl; durch Chlor, Brom oder Methoxy am Ring substituiertes 3-Phenylpropyl; Furfuryl; 2~Thenyl; C -C^-Alkyl; c_-Cr-Alkenyl; C^-C1--Alkinyl; Cinnamyl; mit Chlor, Brom oder Methoxy ara Ring substituiertes Cinnamyl; 3-~?henyl-2~propinyl; C -C17-CyCloalkyl; C^-Co-Cycloalkylmethyl; (Methylcyclopropyl)-methyl; (cis^^-Mmethyl-cyclopropyl)-methyl; Cg-Cg-Cyeloalkenylmethyl; Cg-Cg-Cyeloalkadienyl-methyl;U.S. Patent 3,991,199 discloses hexahydropyrimido- (4,3-b) indoles and their pharmaceutically acceptable salts, useful as analgesics and sedatives, some of which are of tranquillizers, some of which are muscle relaxants, and many of these compounds hypotensive activity; the compounds described have the formula b, wherein the hydrogen atoms bound to the carbon atoms in the 4a and 9b positions are in a trans arrangement with respect to each other and wherein "when Y = -H ', X = -H, -Cl, -Br, -CH-, -tert «~ C ^ H or -OCH, and when Y a = -CF 3 , X a = -H and R has the meaning: hydrogen, 3-chloro-2-butenyl Benzyl, methoxy or chloro; phenethyl, 3-phenylpropyl; 3-phenylpropyl substituted by chlorine, bromine or methoxy on the ring; furfuryl; 2-thenyl; C 1 -C 4 -alkyl; c_-C r -alkenyl; C ^ -C 1 -alkynyl; cinnamyl; cinnamyl substituted with chlorine, bromine or methoxy-ara ring; 3-phenyl-2-propynyl; C-C 17 -cycloalkyl; C 1 -Co-c -Cycloalkylmethyl; (methylcyclopropyl) -methyl; (cis-methylmethyl-cyclopropyl) -methyl; Cg-Cg-cyclooalkenylmethyl; Cg-Cg-cyclooalkadienyl-methyl;
- 3 - S 1 & (Ii i ©- 3 - S 1 & (ii i ©
(2,3-DImethylcycloprop-2-en-1-yl)-methyl; exo-7-Norcarylmethyl; (cis-1f€-Dimethy.lendo-3-norcaren-7-yl)-raethyl; (4-Methylbicyclo /2.2.2._7oct-1-yl)-raethyl· (4-Methylbicyclo /2.2.2_J oct-2-en-1-yl) -methyl« (Bioyclo/2".2.2_7hept-2-yl)-raethyl; (Bicyclo/2\2.2j7hept~2~ en»5-yi)-methyl; 1-Adaraantylrasthyl oder 2~Adaraantylmethyl,(2,3-DImethylcycloprop-2-en-1-yl) methyl; exo-7-Norcarylmethyl; (cis-1 f -dimethy.lendo-3-norcaren-7-yl) -raethyl; (4-methylbicyclo /2.2.2._7oct-1-yl) -raethyl (4-methylbicyclo / 2.2.2_Ioct-2-en-1-yl) -methyl "(Bioyclo / 2" .2.2_7hept-2 yl) -raethyl; (bicyclo / 2 \ 2.2j7hept ~ 2 ~ en »5-yi) -methyl; 1-adaraantyl-3-methyl or 2 ~ adaraantylmethyl,
In der neuerer Zeit veröffentlichten Belgischen Patentschrift 845 368 (Derwerst Hr. 00043Y) sind 5-Phenyl«hexahydro- ^-carboline beschrieben welche gegebenenfalls in den 2- und 4-Stellungen durch Methyl oder Äthyl ViDd in der 3-Stel lung durch Alkyl mit 1 bis 3 Kohlenstoffatomen, Allyl oder Propargyl substituiert sind. Diese Verbindungen sind als Antidepressionsmittel brauchbar.Belgian Patent 845,368 (Derwerst, Hr. 00043Y), recently published, discloses 5-phenyl-hexahydro-carbolines optionally substituted in the 2- and 4-positions by methyl or ethyl ViDd in the 3-position by alkyl 1 to 3 carbon atoms, allyl or propargyl substituted. These compounds are useful as antidepressants.
In der in neuerer Zeit voröffentlichten DE-Offenlegungsschrift 2 63I (Dervjent Nr. O97.38Y)sind strukturell vervjandte Octahydropyrido /4', 3': 2,3_/~ißdolo /1,7-ab_/^/bensazepine beschrieben, die von der zuvor an™ gegebenen Formel abgeleitet v;ferden können, in der .Y eine Athylenbrücke zwischen den beiden Benzol ringet} ist. X ein Wassers toffatora bedeutet und Ra ein Rest -CH2CH2COCH oder -CH2CH2COCgH5 ist. Von diesen Verbindungen -wird ebenfalls angegeben, daß sie als Analgetika und als Tranquilizer brauchbar sind»In more recent unpublished German Offenlegungsschrift 2 631 (Dervjent No. 097.38Y) there are described structurally distributed octahydropyrido / 4 ', 3': 2,3_ / ~ iβdolo / 1,7-ab-1 / benzo-sinepins obtained from can be derived from the formula previously given to ™ in which .Y is an ethylenic bridge between the two benzene . X is a water toffatora and R a is -CH 2 CH 2 COCH or -CH 2 CH 2 COCgH 5 . These compounds are also indicated to be useful as analgesics and tranquilizers. "
In der US-Patentschrift 4 001 263 sind 5-Aryl~1,2,3,4-tetrahydro-jr -U.S. Patent 4,001,263 discloses 5-aryl-1,2,3,4-tetrahydro-jr
carbolJLntranquiliser der Formal σ beschrieben, worin X und Z ein Wasserstoffatom oder Fluoratom sein können, und die Bedeutungen von die Bedeutung, wie zuvor für Ra besitzen kann.carbol-1-n-quaternarymer of the formula σ in which X and Z may be a hydrogen atom or a fluorine atom, and the meanings of the meaning as previously may be for R a .
Überraschenderweise wurde nun gefunden, daß bestimmte neue trans-2,354. 4a,5«9';-i~Hexahydro~1iI-pyrido (45 3-b)-indole .ausgeprägt über le ge no Tran™ quilizeralctivität im Vergleich zu den entsprechenden 1,2,^,h dro- —caiibolinon besitzen.Surprisingly, it has now been found that certain new trans-2,3 5 4. 4a, 5 "9 '; - Hexahydro ~ i ~ 1II-pyrido (4 5 3-b) indoles .ausgeprägt over le ge no Tran ™ quilizeralctivität compared to the corresponding 1,2, ^, h have DRO -cai i bolinon.
tfSSIStfSSIS
Ziel der Erfindung:Object of the invention:
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Zwischenprodukten, die für die Produkte von Verbindungen der Formel II, sowie der pharmazeutisch verträglichen Salze davon wertvoll sind. Diese Endprodukte sind als Tranquilizer einsatzbar, In der Formel II liegen, worin die an die Kohlenstoffatome in den 4a« und 9b-Stellungen gebundenen Wasserstoffatome in einer trans-Anordnung zueinander vor X und ¥„, die gleich oder verschieden sein können, bedeuten ein Wasserstoffatom oder Fluoratom bedeuten, η ist 3 oder 4, M einer der Reste- η t The present invention relates to a process for the preparation of intermediates which are valuable for the products of compounds of formula II, as well as the pharmaceutically acceptable salts thereof. These end products are useful as tranquilizers. In formula II, wherein the hydrogens bonded to the carbon atoms in the 4a and 9b positions are in a trans arrangement to each other before X and y, which may be the same or different, represent a hydrogen atom or fluorine atom, η is 3 or 4, M is one of the radicals η t
-C- oder -CII-, und Z ein Wasserstoffatom, Fluoratom oder einen Msthoxyrest. Die Herstellung dieser Endprodukte ist in der prioritätsgleichen Anmeldung AP C 07 D/205 479 beschrieben.-C- or -CII-, and Z is a hydrogen atom, fluorine atom or a Msthoxyrest. The preparation of these end products is described in the priority application AP C 07 D / 205 479.
Weitere wertvolle Tranquilizer gemäß der Erfindung sind die Enantiomeren «nd racemischen Verbindungen der Formel III, sowie die pharma~ zeutisch annehmbare'Salze hiervon, worin die Wasserstoffatome in den 4a- und 9b"-Stellungen in der gleichen trans-Anordnung wie zuvor vorliegen, X, und Y die zuvor angegebenen Bedeutungen besitzen, m die Zahl 2 oder 3 ist und Z? ein. Fluoratom oder einen Methoxyrest bedeutet«, 'Other valuable tranquilizers according to the invention are the enantiomers and racemic compounds of formula III, as well as the pharmaceutically acceptable salts thereof, wherein the hydrogen atoms in the 4a and 9b "positions are in the same trans arrangement as before, X. and Y are as defined above, m is the number 2 or 3 is a. fluorine atom and Z? or a methoxy radical, ''
Darlegung des Wesens der Erfindung^Explanation of the essence of the invention
Gemäß der Erfindung wird zur· Herstellung von Zwischenprodukten in Form von 4a, 9b~trans~hexahydrocarbolin~Verbindungen der Formel I eine 4as 9b«Hexahydro>-^/*'»carbolin~Verbindung der Formel IV, worin X. mit Y Wasserstoff und R2 Bsnzyl bedeuten, mit Wasserstoff in Gegenwart eines Palladium-Kohlenstoff-Katalysators umgesetzt, Typischerweise -wird die Reaktion untex Verwendung des Hydrochloridsalzes der Verbindung IV bei einer Temperatur von etwa 50 C bis 1000C, Vorzugs»According to the invention, for the preparation of intermediates in the form of 4a, 9b ~ trans ~ hexahydrocarboline ~ compounds of formula I is a 4a s 9b «Hexahydro> - / * '» carbolin ~ compound of formula IV, wherein X. Y is hydrogen and R 2 Bsnzyl reacted with hydrogen in the presence of a palladium-carbon catalyst, typically -is the reaction untex use of the hydrochloride salt of the compound IV at a temperature of about 50 C to 100 0 C, preferably "
•μ K aw fcjfät ** ^*1-^ Vat*·1 >-*>1' • μ K aw fcjfät ** ^ * 1 - ^ Vat * · 1 > - *> 1 '
weise 600C bis 75°C, und Viasserstoff drucken von etwa 1,4 bis 7 kg/Example 60 0 C to 75 ° C, and hydrogen pressure of about 1.4 to 7 kg /
2 cm in Anwesenheit eines reaktisinerten Lösungsmittels wie z.B. Methanol, Äthanol, Isopropanol, Äthylacetat oder Mischungen hiervon mit Wasser durchgeführt« Nach dem Abschluß der Wasserstoffaufnahme ^wird der Katalysator durch Filtration entfernt, und das Hy~ drochloridsalz des Produktes der Formel X wird durch Zugabe eines Nichtlösungsmittels wie beispielsweise Äthyläther, Benzol oder Hexan ausgefällt. Alternativ kann die freie Base der Formel X durch Eindampfen des Filtrats aus der Debenzylierung bis zur Trockene, Verteilung des Rückstandes zwischen wäßrigem Alkali, z, B. Natriumhydroxid, und einem Lösungsmittel wie Chloroform oder Äthyläther isoliert werden. Die freie Base wird dann nach Standardrnethoden, z.B. den zuvor beschriebenen Methoden, isoliert.2 cm in the presence of an acidic solvent, e.g. Methanol, ethanol, isopropanol, ethyl acetate or mixtures thereof with water. After completion of hydrogen uptake, the catalyst is removed by filtration and the hydrochloride salt of the product of formula X is precipitated by the addition of a nonsolvent such as ethyl ether, benzene or hexane , Alternatively, the free base of formula X can be isolated by evaporating the filtrate from the debenzylation to dryness, partitioning the residue between aqueous alkali, e.g., sodium hydroxide, and a solvent such as chloroform or ethyl ether. The free base is then purified by standard methods, e.g. the methods described above, isolated.
Im folgenden wird die Herstellung der Ausgangsmaterialien beschrie«The following describes the preparation of the starting materials. «
o- ^"«carbolin wird nach der Fischer 'sehen Tndolsynthese unter Verwendung von N-,N-Dipheny?.hydra2in und N-3snzyl-4-piperidon erhalten. Die mono- oder di-fluor-substituierten Ausgangstetrahydro- ^—carboline der Formel VIII, worin wenigstens einer der Reste X oder Y ein Fluoratom bedeutet und R? der Benzylrest ist, werden aus den entsprechenden Verbindungen der Formel VIII, ν or in R2 e^-n V/asserstof fatom ist, durch Reaktion mit einem Benzylhalogsnid wie Benzylbroinid in äquiraolaren Mengen hergestellt. Die hierzu erforderlichen Verbindungen der Formel VIII, Rp-H, werden entsprechend den Angaben in der US-Patentschrift 4 001 2β3 hergestellt. Die AuGgangstetrahyd.ro-^-carboline V sind in derselben Druckschrift beschriebeneThe "carboline" is obtained after Fischer's synthesis of T, using N-, N-dipheny- .hydra2in, and N-3snzyl-4-piperidone., The mono- or di-fluoro-substituted starting tetrahydro- ^ -carbolines of ? formula VIII, wherein at least one of X or Y represents a fluorine atom and R is the benzyl radical, are prepared from the corresponding compounds of formula VIII, ν or in R 2 e ^ - n V / asserstof fatom, by reaction with a Benzylhalogsnid The compounds of the formula VIII, Rp-H, which are required for this purpose, are prepared as described in US Pat. No. 4,001,236. The starting tetrahydro-carbolines V are described in the same document
Die anderen Ausgangsmaterialien sind entweder handelsübliche Produkte, ihre Herstellung ist in der chemischen Literatur ausführlich beschrieben oder sie können nach dem Fachmann an sich bekannten Methoden her»The other starting materials are either commercially available products, their preparation is described in detail in the chemical literature or they can be prepared by methods known per se to those skilled in the art.
gestellt -werden. Beispielswelse sind Phenylhydrazine im Handel erhältlich oder sie werden durch Reduktion des Phenyldiazoniurasalzes entsprechend den Angaben vors. Wagner und Zook in "Synthetic organic Chemistry", John Wiley & Sobs, new York, N.Y., 1956» Kapitel 26, hergestellt. Die i-substitulerten-^—Piperidone sind handelsübliche Reagenzien oder sie werden nach der Methode von.McElvain und Rorig, J.AnuChem.Soc, ?O (1948), S* 1826, hergestellt. Die erforderlichen 3-Bensoylpropinsäuren und 4—Benzoylbuttersäuren sind entweder im Handel*erhältlich oder sie werden durch Modifikation der Arbeitsweise entsprechend "Organic Synthesis", Coll. VoI, 2, John Wiley & Sons, Mew York, N.Y., 1943, S. 81 hergestellt.be-made. For example phenylhydrazines are commercially available or they are prepared by reduction of the phenyldiazoniurase salt as described above. Wagner and Zook in Synthetic Organic Chemistry, John Wiley & Sobs, New York, N.Y., 1956 chapter 26. The i-substituted-piperidones are commercial reagents or are prepared by the method of M. McElvain and Rorig, J.Anu. Chem. Soc., O (1948), S * 1826. The required 3-Bensoylpropinsäuren and 4-benzoyl butyric acids are either commercially * available or they are by modification of the procedure according to "Organic Synthesis", Coll. VoI, 2, John Wiley & Sons, Mew York, N.Y., 1943, p. 81.
Ausführungsbeispiel:_Exporting rungsbe ispiel: _
dl~trans-5-Phenyl-2,3J4,4a,599b-hexahydro-1H-pyrido (4,3-b)-indoldl-trans-5-phenyl-2,3 J 4,4a, 5 9 9b-hexahydro-1 H -pyrido (4,3-b) -indole
Eine Suspension von 4,17 g dI--trans~2-Benzyl-5~phenyl-2,3,4,4a,5,9bhexahydro~1H~pyrido(4,3-b)~iKdolhydrochlorid in 150 ml absolutem Äthanol wurde bei 3»5 kp/cm und S0~70 C unter Einsatz von 1,0 g 10 % Ρά/C-Katalysator während einer eitspanne von 2 Stunden hydriert. Der Katalysator wurde durch Filtration entfernt, und zu dem Filtrat wurde ausreichend Athyläther.hinzugesetzt, um das Hydrochlorid des gewünschten Produktes auszufällen; Ausbeute = 2,?6 g (8? %)1 F. 235~237°C,A suspension of 4.17 g of dI-trans-2-benzyl-5-phenyl-2,3,4,4a, 5,9b-hexahydro-1H-pyrido (4,3-b) -α-dihydrochloride in 150 ml of absolute ethanol hydrogenated at 3 »5 kp / cm and S0 ~ 70 ° C using 1.0 g of 10 % Ρά / C catalyst for a period of 2 hours. The catalyst was removed by filtration, and sufficient ethyl ether was added to the filtrate to precipitate the hydrochloride of the desired product; Yield = 2, 6 g (8%) 1 F. 235 ~ 237 ° C,
Das Hydxochloridsalz wurde in die Freie Base durch Verteilung zwischen Äther und verdünnter Natriunihydroxidlb'sting umgewandelt. Die Ätherschicht wurde über Natriumsulfat getrocknet und eingedampft, wobei die in der Überschrift genannte Verbindung in einer Ausbeute von 97 % erhalten wurde; F, 74-76 0C4 The hydroxochloride salt was converted to the free base by partitioning between ether and dilute sodium hydroxide solution. The ether layer was dried over sodium sulfate and evaporated to give the title compound in 97 % yield; F, 74-76 0 C 4
<Ϊ3> SJ %&· .;;.·'<Ϊ3> SJ % & · . ;; · '
N-R.NO.
(I)(I)
(M)(M)
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79939277A | 1977-05-23 | 1977-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD145536A5 true DD145536A5 (en) | 1980-12-17 |
Family
ID=25175793
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD78215015A DD145536A5 (en) | 1977-05-23 | 1978-05-19 | PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO (4,3-B) -INDOLDERIVATE |
| DD215016A DD146186A5 (en) | 1977-05-23 | 1978-05-19 | PROCESS FOR PREPARING A 4A, 9B-HEXAHYDRO-YPSILONE COMPOUND |
| DD78205479A DD138321A5 (en) | 1977-05-23 | 1978-05-19 | PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO POOR CLAIM TO 4,3-B CORNER CLAUSE TO INDOLINE DERIVATIVES |
| DD78215017A DD145537A5 (en) | 1977-05-23 | 1978-05-19 | METHOD OF PREPARING A 4A, 9B-TRANSHEXAHYDRO-GAMMA-CARBOLIN COMPOUND |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD215016A DD146186A5 (en) | 1977-05-23 | 1978-05-19 | PROCESS FOR PREPARING A 4A, 9B-HEXAHYDRO-YPSILONE COMPOUND |
| DD78205479A DD138321A5 (en) | 1977-05-23 | 1978-05-19 | PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO POOR CLAIM TO 4,3-B CORNER CLAUSE TO INDOLINE DERIVATIVES |
| DD78215017A DD145537A5 (en) | 1977-05-23 | 1978-05-19 | METHOD OF PREPARING A 4A, 9B-TRANSHEXAHYDRO-GAMMA-CARBOLIN COMPOUND |
Country Status (31)
| Country | Link |
|---|---|
| JP (1) | JPS53144600A (en) |
| AR (2) | AR217688A1 (en) |
| AT (1) | AT368995B (en) |
| AU (1) | AU499618B1 (en) |
| BE (1) | BE867249A (en) |
| CA (1) | CA1094071A (en) |
| CH (1) | CH634321A5 (en) |
| CS (1) | CS207612B2 (en) |
| DD (4) | DD145536A5 (en) |
| DE (1) | DE2822465C2 (en) |
| DK (1) | DK226678A (en) |
| EG (1) | EG13590A (en) |
| FI (1) | FI63402C (en) |
| FR (1) | FR2392023A1 (en) |
| GB (1) | GB1586655A (en) |
| GR (1) | GR69985B (en) |
| HU (3) | HU185009B (en) |
| IE (1) | IE46975B1 (en) |
| IL (1) | IL54755A (en) |
| IT (1) | IT1096307B (en) |
| LU (1) | LU79684A1 (en) |
| NL (1) | NL7804210A (en) |
| NO (2) | NO150204C (en) |
| NZ (1) | NZ187333A (en) |
| PH (1) | PH13756A (en) |
| PL (5) | PL114547B1 (en) |
| PT (1) | PT68058B (en) |
| SE (2) | SE441448B (en) |
| SU (4) | SU873883A3 (en) |
| YU (4) | YU91478A (en) |
| ZA (1) | ZA782918B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224329A (en) * | 1979-01-23 | 1980-09-23 | Pfizer Inc. | 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles |
| US4451655A (en) * | 1982-05-17 | 1984-05-29 | Pfizer Inc. | Process for preparing carboline derivatives and compounds used in their preparation |
| RU2106864C1 (en) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | New approach to treatment of alzheimer's disease |
| SE9604786D0 (en) | 1996-12-20 | 1996-12-20 | Astra Pharma Inc | New compounds |
| US6974825B1 (en) | 1996-12-20 | 2005-12-13 | Astrazeneca Canada Inc. | Compounds with analgesic effect |
| SE9904675D0 (en) | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
| SE0101773D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101771D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101769D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101770D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR205452A1 (en) * | 1973-12-06 | 1976-05-07 | Endo Lab | METHOD TO PREPARE NEW TRANS-2, 3, 4, 4A, 5, 9B-HEXAHYDRO-5-PHENYL-1H-PYRID (4,3-B) INDOLES |
| JPS50126699A (en) * | 1974-03-20 | 1975-10-04 | ||
| US4001263A (en) * | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
-
1978
- 1978-03-30 SE SE7803625A patent/SE441448B/en unknown
- 1978-04-17 PH PH21013A patent/PH13756A/en unknown
- 1978-04-18 YU YU00914/78A patent/YU91478A/en unknown
- 1978-04-20 NL NL7804210A patent/NL7804210A/en not_active Application Discontinuation
- 1978-04-24 AU AU35377/78A patent/AU499618B1/en not_active Expired
- 1978-04-25 EG EG276/78A patent/EG13590A/en active
- 1978-04-28 AR AR271956A patent/AR217688A1/en active
- 1978-05-18 CS CS783239A patent/CS207612B2/en unknown
- 1978-05-18 GB GB20350/78A patent/GB1586655A/en not_active Expired
- 1978-05-18 PL PL1978206903A patent/PL114547B1/en unknown
- 1978-05-18 PL PL1978215923A patent/PL116944B1/en unknown
- 1978-05-18 PL PL1978215922A patent/PL114541B1/en unknown
- 1978-05-18 PL PL1978215921A patent/PL117107B1/en unknown
- 1978-05-18 HU HU78PI626A patent/HU185009B/en unknown
- 1978-05-18 SU SU782615898A patent/SU873883A3/en active
- 1978-05-18 HU HU822638A patent/HU188802B/en unknown
- 1978-05-18 HU HU822639A patent/HU187782B/en unknown
- 1978-05-19 PT PT68058A patent/PT68058B/en unknown
- 1978-05-19 DD DD78215015A patent/DD145536A5/en unknown
- 1978-05-19 CA CA303,710A patent/CA1094071A/en not_active Expired
- 1978-05-19 DD DD215016A patent/DD146186A5/en unknown
- 1978-05-19 DD DD78205479A patent/DD138321A5/en unknown
- 1978-05-19 BE BE187842A patent/BE867249A/en not_active IP Right Cessation
- 1978-05-19 DD DD78215017A patent/DD145537A5/en unknown
- 1978-05-20 GR GR56281A patent/GR69985B/el unknown
- 1978-05-22 IL IL54755A patent/IL54755A/en unknown
- 1978-05-22 JP JP6087278A patent/JPS53144600A/en active Granted
- 1978-05-22 NO NO781770A patent/NO150204C/en unknown
- 1978-05-22 CH CH552678A patent/CH634321A5/en not_active IP Right Cessation
- 1978-05-22 IT IT23673/78A patent/IT1096307B/en active
- 1978-05-22 NZ NZ187333A patent/NZ187333A/en unknown
- 1978-05-22 ZA ZA00782918A patent/ZA782918B/en unknown
- 1978-05-22 FI FI781612A patent/FI63402C/en not_active IP Right Cessation
- 1978-05-22 DK DK226678A patent/DK226678A/en not_active Application Discontinuation
- 1978-05-22 LU LU79684A patent/LU79684A1/en unknown
- 1978-05-22 IE IE1013/78A patent/IE46975B1/en unknown
- 1978-05-22 AT AT0369678A patent/AT368995B/en not_active IP Right Cessation
- 1978-05-22 FR FR7815029A patent/FR2392023A1/en active Granted
- 1978-05-23 DE DE2822465A patent/DE2822465C2/en not_active Expired
-
1979
- 1979-04-16 AR AR276191A patent/AR221721A1/en active
- 1979-04-24 SU SU792753359A patent/SU843749A3/en active
- 1979-04-26 SU SU792759902A patent/SU818484A3/en active
- 1979-05-18 SU SU792763595A patent/SU841589A3/en active
- 1979-05-18 PL PL20690379A patent/PL206903A1/en unknown
-
1982
- 1982-10-01 YU YU02216/82A patent/YU221682A/en unknown
- 1982-10-01 YU YU2217/82A patent/YU40796B/en unknown
- 1982-10-01 YU YU02218/82A patent/YU221882A/en unknown
-
1983
- 1983-05-20 NO NO831790A patent/NO151862C/en unknown
- 1983-10-27 SE SE8305917A patent/SE448459B/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0173199B1 (en) | Cis, endo-2-azabicycloalkane-3-carboxylic-acid derivatives, processes for their manufacture, their use and intermediate products obtained in their manufacture | |
| DE3784401T2 (en) | CARBOSTYRILE DERIVATIVES AND THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF AND THE CARDIOTONIC COMPOSITION CONTAINING THEM. | |
| EP0253327B1 (en) | Diphenylpropylamine derivatives, their preparation and their pharmaceutical use | |
| DE2733868A1 (en) | NEW 1,2,4,5-TETRAHYDRO-3H-2-BENZAZEPINE-3-ONE, THE METHOD FOR MANUFACTURING IT AND THE MEDICINAL PRODUCTS CONTAINING THESE | |
| DD145536A5 (en) | PROCESS FOR PREPARING TRANS-2-SUBSTITUTED-5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO (4,3-B) -INDOLDERIVATE | |
| DE2453977A1 (en) | NEW FERROCEN COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | |
| EP0222693A2 (en) | 3-Oxadiazolyl and 3-carboxylic-acid beta-carboline derivatives, their preparation and their use as medicaments | |
| DE3309596A1 (en) | 2-SUBSTITUTED 1- (3'-AMINOALKYL) -1,2,3,4-TETRAHYDRO-SS-CARBOLINE, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCT | |
| DE3319956A1 (en) | 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS | |
| DE2362754C2 (en) | Oxazoline compounds containing cyclopropylalkylamino radicals, processes for their preparation and medicaments containing these compounds | |
| DE1695228C2 (en) | 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo- [2,1-a] isoindoles, processes for their preparation and pharmaceuticals containing them | |
| DE2264668A1 (en) | PROPENYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION | |
| EP0266308B1 (en) | Indolo-pyrazino-benzodiazepine derivatives | |
| DE2016721A1 (en) | ||
| DE69818988T2 (en) | 9,10-DIAZATRYCLO [4.2.11 2,5] DECAN- AND 9,10-DIAZATRICYCLO [3.3.1.1 2,6] DECANDERIVE WITH ANALGETIC EFFECT | |
| DE3785987T2 (en) | IMIDAZOLE DERIVATIVES AND THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR COMPOSITIONS. | |
| CH628041A5 (en) | METHOD FOR PRODUCING NEW 4-HYDROXY-2H-NAPHTHO (2,1-E) -1,2-THIAZINE-3-CARBOXAMIDE-1,1-DIOXYDE. | |
| EP0088323B1 (en) | Imidazothiadiazolealkene-carboxylic-acid amides, intermediates used in their preparation, their preparation and their use in medicines | |
| DE3876859T2 (en) | CARDIOTONIC TRICYCLIC OXAZOLONES. | |
| EP0231511B1 (en) | 4-aminoaryldihydropyridine lactones, process for their preparation and their use in medicaments | |
| CH646968A5 (en) | 1,4-DIOXASPIRO (4,5) DECENE COMPOUNDS AND METHOD FOR PRODUCING 2-HYDROXY-3-SUBSTITUTED PROPYLARYLAETHERS. | |
| DE4444860A1 (en) | Use of 1,2-bridged 1,4-dihydropyridines as a drug | |
| DE2417917A1 (en) | PROCESS FOR MANUFACTURING INDOLDER DERIVATIVES WITH A CONDENSED RING SYSTEM | |
| DE1932402B2 (en) | Isopropyl-4-phenyl-3,4-dihydro-2 (1H) quinazolinone derivatives and their further processing to 1-isopropyl-4-phenyl-2 (1H) quinazolinones | |
| DE3048318A1 (en) | 3-Substd.-beta-carboline derivs. - useful as CNS active agents esp. tranquillisers, anticonvulsants |